Welcome to our dedicated page for IPSEN SA news (Ticker: IPSEY), a resource for investors and traders seeking the latest updates and insights on IPSEN SA stock.
Ipsen SA (ADR: IPSEY) generates a steady flow of news centered on its activities as a global, mid-sized biopharmaceutical company focused on Oncology, Rare Disease and Neuroscience. This news page aggregates company announcements, partner releases and regulatory updates that mention Ipsen and its ADR program, giving readers a focused view of developments that can influence perceptions of IPSEY.
Recent news highlights Ipsen’s role in advancing specialty care medicines. In oncology, the company has reported Phase III NAPOLI 3 trial results for an investigational Onivyde-based regimen (NALIRIFOX) in previously untreated metastatic pancreatic ductal adenocarcinoma, with statistically significant improvements in overall and progression-free survival compared to a nab-paclitaxel plus gemcitabine regimen. Ipsen has also nominated a first clinical drug candidate from its multi-year oncology collaboration with Marengo Therapeutics, based on Marengo’s STAR T cell activator platform for solid tumors.
In rare diseases, news items cover Ipsen’s work in pediatric cholestatic liver diseases and ultra-rare conditions. Examples include Health Canada’s approval of Bylvay (odevixibat) for pruritus due to Progressive Familial Intrahepatic Cholestasis, under a partnership with Medison Pharma, and regulatory interactions for palovarotene in fibrodysplasia ossificans progressiva, including a CHMP negative opinion and a U.S. FDA Complete Response Letter. Corporate news also details Ipsen’s agreement to acquire Albireo, adding Bylvay and other bile acid modulators to its rare disease portfolio.
Neuroscience and rare neurological disease updates feature Ipsen’s collaboration with Skyhawk Therapeutics to discover RNA-targeting small molecules for rare neurological diseases. Partner announcements describe Ipsen’s option to obtain exclusive global rights to development candidates and its responsibility for later-stage development and commercialization.
Investors and observers can use this news feed to follow Ipsen’s clinical trial readouts, regulatory decisions, licensing deals, acquisitions and capital markets disclosures that reference IPSEY. Regularly reviewing these updates can help contextualize the company’s therapeutic focus and strategic direction as reflected in public announcements.
IPSEN reported significant trading activity with a total of 8,762 shares exchanged between June 20 and June 23, 2022. The daily weighted average price ranged from 82.7186 to 84.1235, with an overall average of 83.1677. This trading data was sourced from the XPAR platform. The report details individual transactions, emphasizing the total volume and average pricing during the specified period, which is critical for investors monitoring stock performance.
Ipsen announced the acquisition of Epizyme for an all-cash tender offer at $1.45 per share, plus a contingent value right of $1.00 per share. The deal, unanimously approved by both boards, aims to enhance Ipsen's oncology portfolio by focusing on Tazverik®, an EZH2 inhibitor approved for treating specific types of lymphoma. Ipsen anticipates that the acquisition will strengthen its market presence in oncology, despite expected moderate dilution in core operating income until the end of 2024.
Ipsen announced a definitive merger agreement to acquire Epizyme, focusing on Tazverik® (tazemetostat), an EZH2a inhibitor approved in the U.S. The acquisition involves an all-cash tender offer of $1.45 per share and a contingent value right (CVR) of $1.00 per share. Anticipating closure by Q3 2022, this deal enhances Ipsen’s oncology portfolio, aiming for increased sales and leveraging existing infrastructure. The transaction is expected to be moderately dilutive to Ipsen’s core operating income until 2024. Royalty Pharma, holding 20.5% of Epizyme shares, supports the acquisition.
IPSEN has reported its aggregated share acquisition data for the week of June 13-17, 2022. During this period, the company acquired a total of 27,390 shares at a daily weighted average price of €83.6876. The highest daily acquisitions occurred on June 13 with 7,500 shares at an average price of €86.2925, while the lowest was on June 15 with 2,500 shares priced at €84.1820. This information is crucial for investors monitoring IPSEN's share buyback activities.
IPSEN has released a regulatory update detailing the aggregated share transactions conducted on the XPAR platform. On June 6, 2022, a total of 3,500 shares were acquired at a daily weighted average price of €93.7123. Cumulatively, 18,500 shares have been transacted at an average price of €91.8285. The report underlines the company's active share management and compliance with market regulations, emphasizing transparency in financial operations.
Ipsen has reported the total number of shares composing its share capital as of May 31, 2022, which stands at 83,814,526 shares. The gross total of voting rights is 132,125,928, while the net total is 131,073,533. This report aligns with the French Commercial Code regulations.
The net total excludes shares without voting rights, ensuring compliance with statutory obligations concerning threshold crossing declarations.
Ipsen has received a positive opinion in Europe for Dysport® (abobotulinumtoxinA) aimed at treating urinary incontinence in adults with neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis. This approval allows individual European countries to grant national approvals. Dysport® showed significant improvements in clinical trials, reducing incontinence episodes and enhancing bladder capacity. The CONTENT Phase III trial included 485 patients and demonstrated Dysport®'s efficacy in managing symptoms inadequately controlled by oral therapies.
On June 1, 2022, Ipsen announced a total volume of 11,500 shares traded with an average price of €94.2155 across three transactions. The issuer identification code is 549300M6SGDPB4Z94P11, and the financial instrument code is FR0010259150. Each day showed varying volumes; for example, 3,000 shares were traded at €94.2039 on June 1, 2022, while 4,500 shares exchanged at €94.1873 the next day.
Ipsen has appointed an investment-services provider to acquire 125,000 shares, representing approximately 0.15% of its share capital, over a three-month period. This purchase is aligned with the employee free share-allocation plan and was authorized by the Combined Shareholders’ meeting on May 24, 2022.
In FY 2021, Ipsen recorded Specialty Care sales of €2.6 billion, operating in over 100 countries. The company is recognized for its focus on Oncology, Rare Disease, and Neuroscience.
Ipsen (Euronext: IPN; ADR: IPSEY) has announced promising data on Cabometyx® (cabozantinib) to be presented at ASCO 2022, highlighting its efficacy across several cancer types including non-small cell lung cancer (NSCLC) and advanced renal cell carcinoma. The Phase Ib COSMIC-021 study showcases Cabometyx's potential in metastatic NSCLC when combined with atezolizumab. Results from the Phase III COSMIC-311 trial further affirm Cabometyx's effectiveness in treating radioactive iodine-refractory differentiated thyroid cancer. Overall, these findings underscore Cabometyx’s role as a significant treatment option.